Frutarom has announced that its patented HyperPure technology, developed and used to process botanical raw materials in its Swiss facility, will begin U.S. production in the company’s North Bergen, New Jersey plant this month.
“We are very glad to have this environmentally-friendly technology available in the U.S. for the first time,” said Jeffrey Lind, vice president, health business of Frutarom. “This increases our production capacity, allows us to respond more quickly to our customers’ demands, and as with all of our New Jersey-produced ingredients, we now have kosher certified ELFA with a shorter time to market.”
The company said that processing botanical materials presents a spectrum of challenges in balancing removal of undesirable contaminants, maintaining the integrity of the plant’s inherent multi-component system and medicinal compounds, and protecting the environment during the process.
To answer the need for guaranteed product quality, Frutarom developed and patented a highly selective technology, called EFLAHyperPure, to ensure that finished extracts fulfil these requirements. Utilised successfully in Frutarom's pharma grade plant in Wädenswil, Switzerland, the first U.S.-based run will be completed this month.
HyperPure technology has, according to the company, been proven safe and effective. It utilises a specially designed cross flow membrane microfiltration process to separate unwanted lipophilic compounds. Stable, pure and active extracts are obtained without using any harsh solvents.
“The majority of Frutarom’s core products are produced using this technology, including Benolea (olive leaf), Portusana (purslane) and Neuravena (avena/green oat), resulting in ingredients with superior safety and stability,” added Lind.” The addition of proprietary clinical studies behind these products ensures the best combination of high quality, safety and effective natural ingredients.”
